|
1) Karanu FN, Murdoch B, Gallacher L, et al. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med. 2000; 192: 1365-72
|
|
|
|
2) Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus repopulating ability of human CD34(＋)CD38(-) cord blood cells. J Clin Invest. 2002; 110: 1165-74
|
|
|
|
|
|
3) Ueda T, Tsuji K, Yoshino H, et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest. 2000; 105: 1013-21
|
|
|
|
|
|
4) Suzuki T, Yokoyama Y, Kumano K, et al. Highly efficient ex vivo expansion of human hematopoietic stem cells using Delta1-Fc chimeric protein. Stem Cells. 2006; 24: 2456-65
|
|
|
|
|
|
5) Jaleco AC, Neves H, Hooijberg E, et al. Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J Exp Med. 2001; 194: 991-1002
|
|
|
|
|
|
6) de La Coste A, Freitas AA. Notch signaling: distinct ligands induce specific signals during lymphocyte development and maturation. Immunol Lett. 2006; 102: 1-9
|
|
|
|
|
|
7) Cheng P, Nefedova Y, Corzo CA, et al. Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands. Blood. 2007; 109: 507-15
|
|
|
|
|
|
8) 高梨美乃子. 臍帯血バンク, 組織と活動内容. 血液・腫瘍科. 特別増刊号｢造血幹細胞移植のすべて｣. 2007; 55: 325-32
|
|
|
|
|
|
9) Haspel RL, Ballen KK. Double cord blood transplants: filling a niche？ Stem Cell Rev. 2006; 2: 81-6
|
|
|
|
|
|
10) Kunisato A, Chiba S, Nakagami-Yamaguchi E, et al. HES-1 preserves purified hematopoietic stem cells ex vivo and accumulates side population cells in vivo. Blood. 2003; 101: 1777-83
|
|
|
|
|
|
11) Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425: 841-6
|
|
|
|
|
|
12) Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999; 10: 547-58
|
|
|
|
|
|
13) Saito T, Chiba S, Ichikawa M, et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity. 2003; 18: 675-85
|
|
|
|
|
|
14) Mancini SJ, Mantei N, Dumortier A, et al. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood. 2005; 105: 2340-2
|
|
|
|
|
|
15) Han H, Tanigaki K, Yamamoto N, et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol. 2002; 14: 637-45
|
|
|
|
|
|
16) Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006; 443: 421-6
|
|
|
|
|
|
17) Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell. 2005; 9: 617-28
|
|
|
|
|
|
18) Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991; 66: 649-61
|
|
|
|
|
|
19) Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996; 183: 2283-91
|
|
|
|
|
|
20) Chiang MY, Xu ML, Histen G, et al. Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of Notch1. Mol Cell Biol. 2006; 26: 6261-71
|
|
|
|
|
|
21) Weng AP, Nam Y, Wolfe MS, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003; 23: 655-64
|
|
|
|
|
|
22) Weng AP, Ferrando AA, Lee W, et al. Activating mutations of Notch1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306: 269-71
|
|
|
|
|
|
23) Lee SY, Kumano K, Masuda S, et al. Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia. 2005; 19: 1841-3
|
|
|
|
|
|
24) Zhu YM, Zhao WL, Fu JF, et al. Notch1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res. 2006; 12: 3043-9
|
|
|
|
|
|
25) Breit S, Stanulla M, Flohr T, et al. Activating Notch1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006; 108: 1151-7
|
|
|
|
|
|
26) Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006; 6: 347-59
|
|
|
|
|
|
27) Malyukova A, Dohda T, von der Lehr N, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007; 67: 5611-6
|
|
|
|
|
|
28) O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate Notch pathway activation and resistance to {gamma}-secretase inhibitors. J Exp Med. 2007; 204: 1813-24
|
|
|
|
|
|
29) Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006; 20: 2096-109
|
|
|
|
|
|
30) Sharma VM, Calvo JA, Draheim KM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol. 2006; 26: 8022-31
|
|
|
|
|
|
31) Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007; 448: 445-51
|
|
|
|
|
|
32) Vilimas T, Mascarenhas J, Palomero T, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007; 13: 70-7
|
|
|
|
|
|
33) Mungamuri SK, Yang X, Thor AD, et al. Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res. 2006; 66: 4715-24
|
|
|
|
|
|
34) 岩坪 威. アミロイドβペプチドの産生抑制によるアルツハイマー病治療. 日薬理誌. 2002; 120: 30-3
|
|
|
|
|
|
35) Lewis HD, Leveridge M, Strack PR, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol. 2007; 14: 209-19
|
|
|
|
|
|
36) Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24: 6585
|
|
|
|
|